Denver, CO, December 19, 2017 — cliexa, Inc., developer of a mobile platform for chronic disease management, announces today a collaboration with Preventative Technology Solutions, Inc., (PTSI), provider of medical assessment applications and mHealth prevention services for adolescents and young adults. cliexa has licensed PTSI assessment technology to launch cliexa-Options, a suite of behavioral health apps for primary care and family medicine physicians which will help determine risk level for sexual activity, substance use and other issues. UC Health Longmont is piloting the sexual risk assessment app in its clinic and the service is reimbursable by major insurance providers.

Half of the nearly 20 million new sexually transmitted diseases (STDs) reported each year were among young people between the ages of 15 to 24 and nearly 230,000 babies were born to teen girls aged 15–19 years in 2015, according to the CDC. Undiagnosed STDs cause infertility in 20,000 women annually. Facilitating conversations between patients and their physicians is a significant step necessary to reduce costs and chronic conditions often associated with adolescent behavioral health.

cliexa-Options delivers precise, evidence-based assessments that patients complete on a tablet in the physician’s office before their appointment, creating a structured report using proprietary algorithms for each risk area. The reproductive health app supports early identification of patients at highest risk of acquiring an STD or experiencing an unplanned pregnancy. The mental health and substance use apps identify mental health screening, substance use and resiliency in patients.

cliexa is adding cliexa-Options to its award-winning, digital health platform specializing in patient-reported outcomes and value-based care. The company has partnered with Kaiser Permanente Colorado Rheumatology Clinic at Rock Creek and Colorado Permanente Medical Group since 2016, piloting cliexa-RA for rheumatoid arthritis disease management.

“We are excited to partner with PTSI in providing solutions for adolescent behavioral health,” said Mehmet Kazgan, founder and CEO of cliexa. “Our vision is to build an ecosystem for patients and care teams using the most effective and clinically-validated assessment models and patient-reported outcomes. Combining PTSI’s expertise with cliexa’s digital platform creates state-of-the art products in this space.”

“This is an exciting collaboration, and we anticipate being able to serve our medical providers with better digital health technology services in underutilized areas of primary care,” said Scott Fowle, CEO of Preventative Technology Solutions.

About PTSI
Founded in 2015, PTSI provides health promotion software on a service basis for providers who work with adolescents and emerging adults. The apps improve assessment and treatment outcomes for sexual heath, mental health and substance abuse risks, allowing patients to collaborate with providers to establish healthy behaviors. PTSI technology supports access to population data to analyze, and further understand and improve treatment outcomes. Learn more about PTSI at //www.mypreventtech.com.

About cliexa
The mobile platform technology developed by cliexa enable patients to track their chronic disease activity by quantifying symptoms using scientifically-proven and clinically-validated scoring models. cliexa delivers quantified disease activity and medication adherence through patient reported outcomes by real-time integration to electronic medical records which streamlines processes and increases efficiency in population health management.

Learn more about cliexa at //www.cliexa.com

Press Release:

//www.pr.com/press-release/739441

PR.com Official Press Release

Denver, CO, May 02, 2017 –(PR.com)– cliexa-RA, cliexa™’s rheumatoid arthritis app, has been scored among the 19 best RA apps selected from 700+ apps to NIH research:

//www.ncbi.nlm.nih.gov/pmc/articles/PMC5340922/

The review highlights which apps weigh ACR/EULAR treatment guidelines and which include DAS28, among other important features. Researchers rank the apps using the Mobile Application Rating Scale (MARS). A scientific review of mobile apps for tracking rheumatoid arthritis disease activity finds that most apps are either simple calculators for physicians to measure disease activity or tools for patients to track symptoms, most of which do not uniformly collect data using validated instruments or composite disease activity measures.

cliexa’s Co-Founder and CEO Mehmet Kazgan says “cliexa™ changes doctor and patient behavior by connecting patients, clinicians and insurers to better care for and manage chronic conditions which translates into significant cost savings, a better doctor and patient experiences and better outcomes yielding higher customer defined value.” RA Medical Director of cliexa, Dr. Spencer stated that, “In today’s demanding medical environment physicians have limited time to gather relevant data, much less calculate an activity index. With an easily used technology application, patients can be instrumental in helping their doctors determine their disease activity, which, in turn, can lead to better informed treatment decisions. With cliexa-RA we are offering a free mobile application to achieve this goal.”

About cliexa
cliexa staff consists of executive healthcare professionals, physicians, scientists and technologists. cliexa’s first mobile platform, cliexa-RA for Rheumatoid Arthritis has been released to Apple Store in January 2016 and since then, cliexa has developed 3 disease tracking applications, both in iOS and Android platform for Rheumatoid Arthritis (cliexa-RA), Inflammatory Bowel Diseases (cliexa-IBD) and Chronic Obstructive Pulmonary Disease (cliexa-OPD). In November 2016, cliexa has partnered with nation’s biggest payor and provider to run a clinical study with cliexa-RA and raised more than $500K. cliexa platform is a SaaS model offered to end users, clinics, payors and pharma companies for tracking chronic disease symptoms and analytics.

Newswire Official Press Release

cliexa hosted a booth at Rocky Mountain Gastroenterology’s 15th Annual Pow Wow Conference on Saturday, April 9, 2016. Conference was held at Hyatt Regency at Denver Tech Center, Denver, CO.

The GI Pow Wow is designed to provide a gastroenterology & hepatology update to community primary care providers, surgeons, specialists, as well as medical oncologists & radiologists from throughout Colorado and the surrounding region.

Topics included:

  • Opioid receptors & implications on treating Intestinal Disorders
  • Childhood Obesity & Fatty Liver Treatment
  • IBD Treatment update
  • HCV update
  • Esophageal Cancer Prevention
  • Drug-Induced Liver Disease

At a conference with 400 healthcare industry providers, cliexa had a lot of visitors with lot of questions for cliexa-RA which is in Apple store and cliexa-IBD in early May 2016. Lots of physicians showed interest at scientific disease activity scoring which is tracked with both cliexa-RA and cliexa-IBD dynamically.

Our CTO Nathan Blair, CSO Esra Nutku-Bilir and myself have answered questions from different providers. cliexa-IBD for Inflammatory Bowel Disease is using a survey type disease activity scoring whereas cliexa-RA uses DAS28 joint point calculation.

cliexa-IBD has attracted lots of physicians, who are interested in EMR integration with their current systems which is now part of cliexa’s roadmap.

Here are some photos from the exhibition!

Mehmet Kazgan, CEO.

IMG_4211 IMG_4200

PR.com Official Press Release

Feb. 11, 2016 – Collaborative Network 4 Clinical Excellence, LLC (CN4CE) has just launched their first mobile chronic disease tracking application, cliexa-RA. cliexa-RA is available for iOS devices in the App Store. It tracks medications, symptoms and disease activity for Rheumatoid Arthritis. The Clinical Excellence Algorithms concept, cliexa™, is the healthcare technology product line for CN4CE which is built on published and recognized scientific quantitative models that translate chronic disease activity into a scoring model.

The Genesis of cliexa™ originated with the idea of applying mobile technology to help optimize chronic disease care. cliexaTM utilizes mobile applications to help patients more accurately track key disease activity indicators used by their physicians to make decisions about their care plan. While CN4CE focuses on Clinical Excellence Networks (CEN) and Disease Management Algorithms/Protocols, cliexa™ interfaces with end users, enabling patients to track daily chronic disease symptoms as well as medications.

cliexa™ is a powerful communication layer for end users to sync with physicians, clinics and other healthcare providers for disease activity tracking and reporting. It also integrates well with cliexa™ web protocols to update Disease Protocols, managed by Medical Directors (CEN) along with the physicians who are experts in their respective specialties.

CN4CE’s Lance Goudzwaard said, “It is hard to remember your RA symptoms and accurately communicate it to physicians during visits.” Dr. Robert Spencer has been integral in developing cliexa-RA,  a tool which allows RA patients to calculate and follow their disease activity using an accepted disease activity measure called the DAS-28. Dr. Spencer stated that, “In today’s demanding medical environment physicians have limited time to gather relevant data, much less calculate an activity index. With an easily used technology application, patients can be instrumental in helping their doctors determine their disease activity, which, in turn, can lead to better informed treatment decisions.”   With cliexa-RA we are offering a free mobile application to achieve this goal. CN4CE Co-Founder and the Scientific Director Dr. Esra Nutku-Bilir said, “cliexa-RA is one step forward in healthcare. The goal has been to design a tool to provide a service based on a need in healthcare… cliexa-RA is designed to gather real life data, which may provide a service tool for patients, physicians, health insurance companies, pharmaceutical companies, with an immense potential to reach out to every aspect of healthcare, today and in the future”.

Bahri Bilir MD FACP FAASLD, could not hide his excitement: “I found this app to be a very important step in realizing the vision of CN4CE, to provide tools to achieve best outcomes in complex chronic illnesses. The simplicity of this app, will allow patients with RA, without anybody’s help, utilize a well accepted and validated scientific tool, to continuously assess and monitor the activity of their illness. I believe that it will improve their adherence to the medications, when they are in remission. In the possibility of a flare, they will be able to see the warning signs, and reach out to their physicians earlier, before they develop deformities or costly ER visits and hospitalizations.”

CN4CE Co-Founder and CEO Mehmet Kazgan added, “Our ultimate vision is to adapt this modular system to other chronic diseases where certain data or clinical indices have been shown to have evidence-based utility in disease and treatment monitoring.”

About CN4CE
CN4CE staff consists of executive healthcare professionals, physicians, scientists and technologists. CN4CE was founded originally in 2011 focusing on Dr. Bahri Bilir’s evidence based disease algorithms concept which has a patent pending status.